VC Deals

Chemistry Ventures, a venture capital firm founded by alumni of Bessemer Venture Partners, Index Ventures, and Andreessen Horowitz, has announced it is raising $500 million for its second fund. The firm's ability to close such a substantial capital raise for Fund II—before Fund I has likely demonstrated any meaningful exit velocity—represents a masterclass in one of venture capital's most reliable value extraction mechanisms: brand-stacking. These are not entrepreneurs pitching a new technology or business model. These are VCs pitching other VCs on the revolutionary concept that people who worked at famous VCs might be good at doing VC.

Chemistry Ventures has taken what should be the baseline requirement for a VC partnership—that its founders have worked in venture capital—and transformed it into the entire investment thesis. The firm's positioning depends entirely on the assumption that being previously employed at Bessemer, Index, or Andreessen is so inherently valuable that it can serve as both the primary credential and the primary selling point to limited partners. This is not a fund built on proprietary deal flow, technical expertise, or a differentiated thesis about emerging market categories. It is a fund built on the portable prestige of three very good previous employers. Limited partners, apparently, are paying $500 million to bet that competence is hereditary in VC.

The timing is worth noting. Chemistry Ventures is raising Fund II—meaning the firm has already deployed Fund I and is asking LPs to double down—during a period when the broader venture ecosystem is experiencing significant contraction, when many portfolio companies are burning cash at alarming rates, and when the IRR bar for returning capital has climbed considerably. Yet the firm's pedigree appears to have inoculated it from the skepticism now directed at funds without such ornamental credentials. This is the VC version of a credit rating: it matters less what you've actually built than whose nameplate you carried on your business card.

The press release language, when it arrives, will be instructive. Expect phrases like "platform for exceptional founders," "deep operational experience," and "conviction-driven investing." What these terms actually mean is: "We hired people from other successful funds and are confident you will pay us to repeat this process indefinitely." The "operational experience" will be defined as having sat in board meetings at firms that made successful investments. The "platform" will consist of Rolodex access and the ability to return phone calls from other people with Bessemer, Index, or Andreessen in their recent employment history.

Fund II's success will be determined by whether Chemistry's portfolio companies can exit at the valuations necessary to return 2.5x to 3x gross multiples to LPs—the gravitational baseline for a mid-market VC fund in this climate. The question that matters is not whether the founders are smart (they probably are) or well-connected (they certainly are). The question is whether their previous employers' brand equity translates into deal quality better than the market average. History suggests that it doesn't, and that brand-stacked teams often underperform precisely because they are selected more for lineage than for actual edge.

This capital raise is a referendum on LP discipline. It suggests that limited partners remain willing to bet on resume over track record, and that in venture capital, the three most valuable words remain "formerly at Andreessen." Chemistry Ventures has not yet proven its thesis; it has simply proven that proving one's thesis is optional if one's founders worked somewhere sufficiently prestigious. The $500 million raise is not an endorsement of Chemistry's investment acumen. It is a confirmation that in VC, brand-stacking—layering prestigious prior employment into a consultancy selling investment access—remains the most reliable business model of all.